BUSINESSAug 3 · 07:52 UTCCNBC TOP

AstraZeneca shares drop 7% after report on $400 billion merger talks with Bristol Myers Squibb

AstraZeneca shares fell 7% following a Financial Times report indicating the company has discussed a potential merger with Bristol Myers Squibb over several months.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

AstraZenecaorganizationBristol Myers SquibborganizationFinancial Timesorganization

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

BUSINESSAug 3 · 08:09 UTC
AstraZeneca holds talks with Bristol Myers Squibb over £300bn merger
BUSINESSAug 2 · 20:12 UTC
AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports
BUSINESSAug 3 · 07:08 UTC
AstraZeneca holds talks with Bristol Myers Squibb on $400bn merger
BUSINESSAug 3 · 07:08 UTC
AstraZeneca holds talks with Bristol Myers Squibb on $400bn merger
BUSINESSAug 3 · 05:46 UTC
AstraZeneca Is Said to Have Explored Bristol Myers Merger
BUSINESSAug 2 · 21:27 UTC
AstraZeneca said to have explored Bristol Myers merger